Skip to content

Efficacy and Safety of Propionibacterium Extract Gel Versus 0.4% Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: a Randomised Controlled Trial

Efficacy and Safety of Propionibacterium Extract Gel Versus 0.4% Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: a Randomised Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05616455
Enrollment
120
Registered
2022-11-15
Start date
2021-10-01
Completion date
2022-05-31
Last updated
2022-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Fissure Chronic, Anal Fissure

Brief summary

The study compares the efficacy and safety of a Propionibacterium extract gel with 0.4% glyceryl trinitrate ointment in the treatment of chronic anal fissure.

Detailed description

Patients were randomly allocated to a PeG or GTN group and medication was taken every 12 hours for 40 days. Primary outcome was the success rate as measured by a decrease in the REALISE score at 10, 20 and 40 days after starting either treatment. The secondary out-comes were the healing rate, the partial or complete resolution of itching and burning, the rate of complications and adverse events, patients' quality of life and satisfaction at the same time points.

Interventions

Application of the gel every 12 hours for 40 days

DRUGPropionibacterium Acnes

Application of the gel every 12 hours for 40 days

Sponsors

Treviso Regional Hospital
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Healthy volunteers
No

Inclusion criteria

* Consecutive patients diagnosed with chronic anal fissure aged between 18 and 75 years

Exclusion criteria

* Fecal incontinence * Inflammatory bowel disease * Previous history of anal surgery * Previous or concomitant treatment for anal fissure, sexually transmitted disease, cancer, immune-suppressive treatment * Current pregnancy or breastfeeding * Known allergy to one of the agents contained into the evaluating drugs

Design outcomes

Primary

MeasureTime frameDescription
REALISE scoreFrom baseline to visit 3 (40 days after the start of the treatment)REALISE (scoRing systEm for AnaL fIsSurE), was used to assess pain (minimum score = 0, maximum score = 10)

Secondary

MeasureTime frameDescription
BurningFrom baseline to visit 3 (40 days after the start of the treatment)Visual analogue scale (VAS) (minimum score = 0, maximum score = 10)
ItchingFrom baseline to visit 3 (40 days after the start of the treatment)Visual analogue scale (VAS) (minimum score = 0, maximum score = 10)
EpithelializationFrom baseline to visit 3 (40 days after the start of the treatment)The degree of epithelialization of the fissure was determined at each visit and stratified using 3 levels (1 to 3) corresponding to \<50%, \>50% of healing or complete healing, respectively.
Physical and mental healthFrom baseline to visit 3 (40 days after the start of the treatment)Short-Form 12 (SF-12)
Patients' satisfactionAt visit 3 (40 days after the start of the treatment)VAS (1 = unsatisfied; 2 = neutral; 3 = quite satisfied; 4 = very satisfied; 5 = extremely satisfied)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026